BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22584320)

  • 1. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
    Sato A; Hamada K; Imataka H
    Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strategy for patients with GIST after failure of imatinib].
    Abe S; Kubota T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):540-3. PubMed ID: 19381023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
    J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
    Láng I; Hitre E
    Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GIST refractory to imatinib treatment].
    Onozawa Y; Terashima M
    Gan To Kagaku Ryoho; 2011 May; 38(5):738-43. PubMed ID: 21566433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali.
    Diallo DA; Ly M; Diallo G; Dembélé AK; Touré M; Touré BA; Koné A; Sidibé S; Dembelé M; Traore BC
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):675-7. PubMed ID: 21641899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
    Nishimura T; Sakata K; Maeda Y; Nagashima Y; Okada T; Nakamura M; Setoguchi M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2202-4. PubMed ID: 22202330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW; Colombo C
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contemporary treatment of gastrointestinal stromal tumors].
    Nishida T
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1639-44. PubMed ID: 18931562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM; Amand MS; Demetri GD
    Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel molecular-targeted agents for GIST(Regorafenib etc.)].
    Naito Y; Doi T
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):15-8. PubMed ID: 23306914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
    Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
    Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
    Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
    Gulati AP; Saif MW
    Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.